Climb Bio, Inc. (CLYM)
9.19
-0.09
(-0.97%)
USD |
NASDAQ |
Nov 20, 16:00
9.19
0.00 (0.00%)
After-Hours: 20:00
Climb Bio Research and Development Expense (TTM) : 43.60M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 43.60M |
| June 30, 2026 | 41.83M |
| March 31, 2026 | 38.72M |
| December 31, 2025 | 46.71M |
| September 30, 2025 | 38.93M |
| June 30, 2025 | 33.38M |
| March 31, 2025 | 27.85M |
| December 31, 2024 | 11.61M |
| September 30, 2024 | 8.782M |
| June 30, 2024 | 8.14M |
| March 31, 2024 | 10.78M |
| December 31, 2023 | 15.41M |
| Date | Value |
|---|---|
| September 30, 2023 | 17.21M |
| June 30, 2023 | 18.59M |
| March 31, 2023 | 23.67M |
| December 31, 2022 | 26.21M |
| September 30, 2022 | 28.17M |
| June 30, 2022 | 29.90M |
| March 31, 2022 | 26.92M |
| December 31, 2021 | 23.32M |
| September 30, 2021 | 18.39M |
| June 30, 2021 | 13.76M |
| March 31, 2021 | 9.591M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Korsana Biosciences, Inc. | 43.39M |
| Cullinan Therapeutics, Inc. | 169.67M |
| Q32 Bio, Inc. | 15.94M |
| Oncolytics Biotech, Inc. | 13.18M |
| Sangamo Therapeutics, Inc. | 113.79M |